Novo Nordisk cuts profit forecast as new CEO faces rocky start

Core Viewpoint - Novo Nordisk has lowered its full-year profit forecast, presenting an early challenge for the newly appointed CEO Mike Doustdar as the company faces slowing sales and a rapidly evolving obesity drug market [1] Company Summary - The company is experiencing challenges in its sales performance, which has led to a revision of its profit outlook for the year [1] - The newly appointed CEO, Mike Doustdar, is tasked with navigating these challenges in a competitive and changing market [1] Industry Summary - The obesity drug market is undergoing significant changes, impacting sales dynamics for companies like Novo Nordisk [1] - The slowing sales trend indicates potential shifts in consumer demand or competitive pressures within the obesity treatment sector [1]